<?xml version='1.0' encoding='utf-8'?>
<document id="29947477"><sentence text="Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus." /><sentence text="SCY-078 is an orally bioavailable triterpenoid glucan synthase inhibitor in clinical development as an intravenous and oral treatment of fungal infections caused by Candida and Aspergillus species"><entity charOffset="34-46" id="DDI-PubMed.29947477.s2.e0" text="triterpenoid" /></sentence><sentence text=" This was a sequential, single-center, open-label phase 1 study to assess the drug-drug interaction potential between SCY-078 and tacrolimus during concomitant administration in healthy subjects"><entity charOffset="130-140" id="DDI-PubMed.29947477.s3.e0" text="tacrolimus" /></sentence><sentence text=" In cohort 1, period 1, subjects received a single oral dose of tacrolimus 2 mg in the fasted state"><entity charOffset="64-74" id="DDI-PubMed.29947477.s4.e0" text="tacrolimus" /></sentence><sentence text=" In period 2 after a ≥15 day washout, subjects received a single loading dose of SCY-078 1250 mg on day 1 followed by maintenance doses of SCY-780 750 mg on days 2 through 8" /><sentence text=" On day 3 of period 2, subjects also received a single dose of tacrolimus 2 mg concurrent with SCY-078"><entity charOffset="63-73" id="DDI-PubMed.29947477.s6.e0" text="tacrolimus" /><entity charOffset="95-102" id="DDI-PubMed.29947477.s6.e1" text="SCY-078" /><pair ddi="false" e1="DDI-PubMed.29947477.s6.e0" e2="DDI-PubMed.29947477.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29947477.s6.e0" e2="DDI-PubMed.29947477.s6.e1" /></sentence><sentence text=" In cohort 2, subjects received a loading dose of SCY-078 1250 mg on day 1 followed by maintenance doses of SCY-780 750 mg on days 2 and 3" /><sentence text=" Pharmacokinetic (PK) parameters were compared to assess both the impact of steady-state SCY-078 on tacrolimus and the impact of tacrolimus on the PK of steady-state SCY-078"><entity charOffset="100-110" id="DDI-PubMed.29947477.s8.e0" text="tacrolimus" /><entity charOffset="129-139" id="DDI-PubMed.29947477.s8.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.29947477.s8.e0" e2="DDI-PubMed.29947477.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29947477.s8.e0" e2="DDI-PubMed.29947477.s8.e1" /></sentence><sentence text=" The concurrent coadministration of tacrolimus and SCY-078 had no effect on the maximum blood levels of tacrolimus, as evidenced by no change in maximum concentration of drug in blood plasma and a 1"><entity charOffset="36-46" id="DDI-PubMed.29947477.s9.e0" text="tacrolimus" /><entity charOffset="51-58" id="DDI-PubMed.29947477.s9.e1" text="SCY-078" /><entity charOffset="104-114" id="DDI-PubMed.29947477.s9.e2" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.29947477.s9.e0" e2="DDI-PubMed.29947477.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29947477.s9.e0" e2="DDI-PubMed.29947477.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29947477.s9.e0" e2="DDI-PubMed.29947477.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29947477.s9.e1" e2="DDI-PubMed.29947477.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29947477.s9.e1" e2="DDI-PubMed.29947477.s9.e2" /></sentence><sentence text="4-fold increase in total area under the plasma drug concentration-time curve" /><sentence text=" The concurrent coadministration of tacrolimus and SCY-078 resulted in a weaker interaction than typically observed with the azole class of antifungals"><entity charOffset="36-46" id="DDI-PubMed.29947477.s11.e0" text="tacrolimus" /><entity charOffset="51-58" id="DDI-PubMed.29947477.s11.e1" text="SCY-078" /><entity charOffset="125-130" id="DDI-PubMed.29947477.s11.e2" text="azole" /><pair ddi="false" e1="DDI-PubMed.29947477.s11.e0" e2="DDI-PubMed.29947477.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29947477.s11.e0" e2="DDI-PubMed.29947477.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29947477.s11.e0" e2="DDI-PubMed.29947477.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29947477.s11.e1" e2="DDI-PubMed.29947477.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29947477.s11.e1" e2="DDI-PubMed.29947477.s11.e2" /></sentence><sentence text=" The current data indicate that an initial dose adjustment for tacrolimus may not be warranted when combined with SCY-078, as the modest increase in exposure is less than the therapeutic window, although tacrolimus monitoring, as with addition of any new medication, is recommended"><entity charOffset="63-73" id="DDI-PubMed.29947477.s12.e0" text="tacrolimus" /><entity charOffset="114-121" id="DDI-PubMed.29947477.s12.e1" text="SCY-078" /><entity charOffset="204-214" id="DDI-PubMed.29947477.s12.e2" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.29947477.s12.e0" e2="DDI-PubMed.29947477.s12.e0" /><pair ddi="false" e1="DDI-PubMed.29947477.s12.e0" e2="DDI-PubMed.29947477.s12.e1" /><pair ddi="false" e1="DDI-PubMed.29947477.s12.e0" e2="DDI-PubMed.29947477.s12.e2" /><pair ddi="false" e1="DDI-PubMed.29947477.s12.e1" e2="DDI-PubMed.29947477.s12.e1" /><pair ddi="false" e1="DDI-PubMed.29947477.s12.e1" e2="DDI-PubMed.29947477.s12.e2" /></sentence><sentence text=" These results support the coadministration of SCY-078 and tacrolimus"><entity charOffset="47-54" id="DDI-PubMed.29947477.s13.e0" text="SCY-078" /><entity charOffset="59-69" id="DDI-PubMed.29947477.s13.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.29947477.s13.e0" e2="DDI-PubMed.29947477.s13.e0" /><pair ddi="false" e1="DDI-PubMed.29947477.s13.e0" e2="DDI-PubMed.29947477.s13.e1" /></sentence><sentence text="" /></document>